Advertisement

BMC Infectious Diseases

, 19:5 | Cite as

CRYPTOCOCCAL meningitis in a HIV negative newly diagnosed diabetic patient: a CASE report

  • Odhiambo Henry OwuorEmail author
  • Patrick Chege
Open Access
Case report
  • 216 Downloads
Part of the following topical collections:
  1. Bacterial and fungal diseases

Abstract

Background

This case report emphasizes the need to recognize cryptococcus as a possible cause of meningitis in non-HIV patients in Sub-Saharan Africa and to highlight the possibility of grave outcomes due to the paradoxical immune response in diabetic patients with cryptococcus meningitis. It also highlights the need for widespread availability of amphotericin-B and flucytosine in hospitals in Sub-Saharan Africa.

Case presentation

A 27 year old African lady was admitted with generalized tonic clonic seizures lasting 5 to 10 min. These seizures were preceded by severe frontal headaches radiating to the occiput and neck and associated with chills, photophobia and loss of consciousness. She was tachycardic and had tongue bites on the lateral aspects of her tongue. Kernig’s and Brudzinski’s signs were positive. India ink was positive on two cerebrospinal fluid (CSF) samples. She had hyperglycemia and glucosuria as well. She was diagnosed with cryptococcal meningitis in diabetes and had a remarkable response to fluconazole monotherapy. She went home on maintenance dose of fluconazole having made full recovery. and is currently on prophylactic doses of fluconazole.

Conclusions

With the rising prevalence of diabetes in Sub-Saharan Africa, coupled with the low levels of adequate glucose control, cryptococcal meningitis should be considered in the differential diagnosis for diabetic patients presenting with chronic headache, fever and neurologic deficits.

Keywords

Cryptococcal meningitis Diabetes Fluconazole HIV negative 

Abbreviations

AL

Artemether-lumefantrine

BD

Twice a day

BP

Blood pressure

BS for MPS

Blood slide for malaria parasites

CSF

Cerebro-spinal fluid

ESR

Erythrocyte sedimentation rate

FBS

Fasting blood sugar

FHG

Full hemogram

HIV

Human immunodeficiency virus

IU

International units

IV

Intravenous

LP

Lumber puncture

OD

Once a day

PCM

Paracetamol

PITC

Provider initiated testing and counseling for HIV

PRN

When necessary

QID

Four times a day

RBS

Random blood sugar

RUQ

Right upper quadrant

SPO2

Peripheral capillary oxygen saturations

TID

Three times a day

UECs

Urea, electrolytes and creatinine

VDRL

Venereal disease research laboratory

ZN

Ziehl–Neelsen

Background

Cryptococcus neoformans is an opportunistic fungus that causes infection of the central nervous system in those who are immunocompromised, particularly in human immunodeficiency virus (HIV) patients [1]. It infrequently infects HIV-negative persons such as post-organ transplant patients and those with diabetes mellitus, liver cirrhosis and alcoholism [1]. Inadequate glucose control in diabetic patients increases their risk to infections due to numerous factors especially the glucose-rich blood which is media for micro-organism growth [2, 3, 4]. Remarkably, diabetic patients mount dramatic immune responses to cryptococcus that are paradoxical to their immunosuppressive state. Studies have shown that optimal control of blood sugar levels in diabetic patients in Sub-Saharan Africa is very low [5, 6, 7]. This case report emphasizes the need to recognize cryptococcus as a possible cause of meningitis in non-HIV patients in Sub-Saharan Africa and to highlight the possibility of grave outcomes due to the paradoxical immune response in diabetic patients with cryptococcal meningitis. The case report also highlights the need for widespread availability of amphotericin-B and flucytosine in hospitals in Sub-Saharan Africa.

Case presentation

A 27 year old African lady, from Bungoma County in Western Kenya, was admitted with generalized tonic clonic seizures lasting 5 to 10 min. This was associated with loss of consciousness for 10–20 min and left sided hemiparesis that lasted nearly 30 min after the convulsion. These symptoms had lasted one day but had been preceded by severe frontal headache radiating to the occiput and neck, chills, and photophobia for three days. Her past medical history was significant for peptic ulcer disease and allergic rhino-sinusitis for which she uses omeprazole, antacid and celestamine intermittently. Social history is notable for a diabetic twin sister who had been on insulin. The twin sister had died of pneumonia three days to the patient’s admission. The patient’s mother died ten years ago due to complications associated with diabetes. She is separated from her husband but she stays with her six year old daughter. The patient runs a small pharmacy business. She had travelled with her twin sister to a funeral before they fell sick.

The patient had been sickly for a month before this admission. She had had severe frontal headaches associated with chills and photophobia. She had also complained of frequency of micturition and increased intake of water. There was no weight loss. She was treated with artemether-lumefantrine (AL) at a health center for malaria (blood slide was positive for P. falciparum). There was improvement for two weeks. However, the headache and photophobia recurred while polyuria and polydypsia persisted. She sought medical attention in a different health center where she was diagnosed with severe malaria and diabetes. Metformin was instituted in addition to quinine and AL. She developed the convulsions on the third day of treatment and was brought to our facility.

Clinical findings

Her vital signs was notable for tachycardia (pulse was 112 beats/min). Her blood pressure (BP) was 114/75 mmHg, saturations 93%, respiratory rate was 15 cycles/min, and temperature was 36.7 °C. She had bites on the lateral aspects of her tongue, an equivocal neck and positive Kernig’s and Brudzinski’s signs. Reflexes and remainder of her physical exam was normal.

Timeline

Date

Relevant Patient Data

December 3, 2017 (day 1/admission date)

Patient admitted with:

Severe headaches;

Convulsions;

Difficulty swallowing;

Polyuria;

Polydipsia;

Tachycardia;

Positive Kernig’s;

Right upper quadrant (RUQ) tenderness;

Diagnosed with bacterial meningitis in a diabetic; with differentials of cerebral malaria, brain abscess;

Labs

1. FBS: 19.1 mmol/l Daily FBS

2. PITC: non-reactive;

3. LP for CSF analysis: biochemistry, microscopy, India ink, ZN staining.

4. ESR: 87 mm/hr.;

5. BS for MPS: 20 parasites per 200 wbcs;

6. FHG, UECs, CT scan: patient did not do these because of lack of funds;

7. Urinalysis: ph = 7.0; glucose +++; blood ++; SG 1.010; ketones nil; deposit: nothing seen.

8. Abdominal ultrasound: normal abdominal scan, no renal or splenic abscess.

Treatment:

1. Diazepam 10 mg PRN

2. Artesunate: 180 mg at 0, 12 and 24 h;

3. Ceftriaxone 2 g BD for 10 days;

4. Paracetamol 1 g tid

5. Metformin 500 mg bd

6. Dentogel cream apply QID on the oral lesions for 5 days.

7. IV fluids 4 l of normal saline in 24 h

Day 2

Patient had four convulsions last night. Another which was partial occurs during the round.

On examination: left sided paresis noted. All vitals including heart rate were now normal.

Results:

1. CSF: turbid; 60 cells/mm3; Pandy test negative; India ink positive; gram stain: no organism isolated; ZN negative; VDRL: negative.

2. FBS = 17.4 mmol/l;

3. I.V phenytoin 100 mg BD

4. Fluconazole 1200 mg od for 2 weeks, then 400 mg od for 10 weeks; then 200 mg od for 6 months.

5. Daily FBS; do UECs, FHG, CT scan of the head, TSH

6. Continue with ceftriaxone, metformin, PCM, dentogel, and artesunate,

7. Monitor for seizure occurrence and chart

Day 3

Reports improvement with no seizures reported; patient is now able to feed, has mild headaches.

FBS not reported;

Vitals normal (BP = 112/72 mmHg, pulse 97 bpm, SPO2 = 94%);

Neck is soft and Kernig’s negative.

Plan: continue with fluconazole, ceftriaxone, phenytoin, paracetamol, aremether-lumefantrine

Day 4–6

Reports some neck pains and headaches;

On examination, patient is in fair general condition, vitals are normal;

Neck is soft and Kernig’s negative;

FBS oscillates between 13 and 14 mmol/l;

Plan: continue with medication, do nutritional counseling because of diabetes;

Day 7

Patient complaints of frontal headache, itchiness on areas that had strapping used to secure IV lines, and gluteal itchiness

FBS = 13.7 mmol/l;

Patient is once again sick looking, with normal vitals (BP = 116/79 mmHg; SPO2 = 95%; pulse = 85)

Neck is stiff and tongue lesions are still present on the edge of the tongue;

Pruritic pustules on the areas with strapping, buttock has no eruptions;

Plan:

1. I.M diclofenac 75 mg PRN;

2. hydrocortisone cream to apply bd;

3. soluble insulin 5 IU tid;

4. continue antimeningitics and phenytoin;

5. do daily pre-dinner RBS and FBS.

Day 8

Patient still complaining of severe headache despite administration of three doses of diclofenac; the tongue ulcer is still painful and she is still itching;

Patient is sick looking but with normal vitals;

She still has the stiff neck, rashes and the tongue ulcers;

Plan:

1. 4mls of clear CSF tapped and sent for microscopy: India ink positive;

2. Continue with the medication from the previous day.

Day 9

The headaches have improved and her vitals are normal;

FBS = 20.9 mmol/l;

Plan:

1. stop the insulin;

2. increase metformin to 1 g bd;

3. continue with other medication.

Day 10–13

Patient reports improvement and her vitals are normal.

RBS ranged between 8.0 and 13.1 mmol/l.

Plan:

1. continue with management as per treatment sheet i.e. ceftriaxone, fluconazole, metformin, glibenclamide, hydrocortisone cream and dentogel.

2. Do serial CSF tapping if headaches are persistent.

Day 14

Patient has no complaints today.

FBS = 8 mmol/l.

Plan:

1. Allow home on metformin 750 mg bd;

2. Fluconazole 800 mg od for two weeks then 400 mg for 10 weeks;

3. Dentogel, hydrocortisone cream, and omeprazole.

4. To come again on 12th January 2018.

1st clinic visit (January 11, 2018)

Patient is doing well except for a flare up of her allergic rhino-sinusitis. Blood sugar was 5.8 mmol/l and a repeat lumber puncture was negative on India ink test.

The need for dietary prudence and drug adherence was emphasized. She was then given fluconazole 800 mg od and asked to continue with metformin 750 mg bd, cetirizine 10 mg prn, omeprazole 20 mg bd and hydrocortisone.

2nd clinic visit (January 25, 2018)

Patient diagnosed with pneumonia;

RBS = 8.2 mmol/l; BS for MPS was negative; CSF for India ink was negative for Cryptococcus;

Plan:

-septrin 960 mg bd for one week;

-paracetamol 1 g tid for 5 days;

-omeprazole 20 mg 1 h before supper for a month;

-fluconazole 800 mg od for a month;

-metformin 500 mg bd for a month;

Diagnostic assessment

Her initial lab results showed 20 malaria parasites/200WBCs on a blood slide, a random blood sugar of 19.1 mmol/l, HIV non-reactive, ESR 87 mm/hr., cerebro-spinal fluid (CSF): turbid, 60 cells/mm3, pandy test negative, Indian ink positive, gram stain: no organism isolated, Ziehl–Neelsen stain (ZN) negative, venereal disease research laboratory (VDRL): negative; full hemogram (FHG), urea, electrolytes and creatinine (UEC) & CT scan: patient did not do these because of lack of funds; urinalysis: ph = 7.0, glucose +++, blood ++, SG 1.010, ketones nil, deposit: nothing seen; abdominal ultrasound: normal abdominal scan, no renal or splenic abscess. Fundoscopy neither revealed malarial retinopathy nor papilledema. We could not get a CT scan, urea/electrolytes/creatinine and a full hemogram/complete blood count done due to the patient’s financial status.

Intervention

The patient was started on diazepam 10 mg PRN, artesunate: 180 mg at 0, 12 and 24 h, ceftriaxone 2 g BD for 10 days, paracetamol 1 g tid and metformin 500 mg bd. Fluconazole 1200 mg od for 2 weeks was initiated due to the unavailability of amphotericin B and flucytosine. Convulsions ceased on the third day. There was improvement over the next few days but on the eighth day there was severe headache, neck stiffness and positive Kernigs sign. Serial tapping was done to relieve the headaches.

Follow-up and outcomes

After 2 weeks and with marked improvement, the patient was allowed home on metformin 750 mg bd, fluconazole 800 mg od for ten weeks. A repeat CSF analysis was negative for Indian ink after two weeks of treatment. She has been free of symptoms since she was allowed home. Metformin dose was reduced to 500 mg bd because her blood sugar was controlled and ranging between 5 and 8 mmol/l. She was counseled on lifestyle modification, particularly on diet and exercise to enhance control of diabetes. Other findings during her follow up are as outlined in the ‘Timeline’ table.

Discussion and conclusions

Cryptococcus neoformans is an opportunistic fungus that causes infection of the central nervous system in those who are immunocompromised, particularly in human immunodeficiency virus (HIV) patients [1]. It is rarely reported as a cause of meningitis in HIV seronegative patients in Sub-Saharan Africa. However, it may infect persons with other immunosuppressed systems like patients on chronic glucocorticoid use, malignancy, sarcoidosis and liver failure [1]. Sub-Saharan Africa is experiencing an increasing prevalence of diabetes [2]. Of note is that low levels of adequate glucose control are achieved in diabetic patients who are on any form of treatment [3, 4]. This is bound to increase the occurrence of cryptococcal meningitis in non HIV non transplant patients, who are predominantly diabetic patients.

C. neoformans is acquired through inhalation. From the respiratory tract it causes disseminated disease with a propensity for the central nervous system (neourotopism). Sometimes it may spread to the bone, prostate, skin, eyes and liver [1, 8]. Cryptococcal meningitis can present as fever, malaise, headache, vomiting, meningeal signs, seizures and cranial nerve palsies [8, 9]. These features tend to be sub-acute with the headache evolving over 2–4 weeks [10].

Diabetic patients with poorly controlled blood sugars are more prone to infections since the glucose-rich blood serves as an excellent media for growth. Cryptococcal infections in these patients are severe. Hyperglycemia causes impaired granulocyte chemotaxis, phagocytosis and deficient cell-mediated immunity, which is the most important host response to cryptococcal infection. Elevated serum levels of TNF-α and interleukin-6 in patients with diabetes let them mount an exaggerated immune response to C. neoformans [5, 6, 7]. This milieu is a recipe for infections to lead to fatal outcomes as reported by Kushawaha and colleagues in their case report [1].

This lady was on the alternative regimen for treating cryptococcal meningitis in adults [11]. In the induction phase, she was given fluconazole 1200 mg od for two weeks. This was followed by 800 mg of fluconazole for the consolidation phase of 8 weeks and 400 mg for the maintenance phase. CSF sterilization was confirmed in the fourth week and the patient has remained asymptomatic. This is in contrast to the recommended combination of amphotericin B and flucytosine for the induction phase that provides greater fungicidal activity, early CSF sterilization, lower rates of treatment failure and lower mortality [12, 13, 14, 15].

Due to the exaggerated immune response, some scholars offer that anti-inflammatory medication like corticosteroids may have an adjunctive role in the management of cryptococcal meningitis in diabetic patients [1, 16]. Lack of a CT scan, and inability to estimate serum cryptococcal antigen or to do a CSF culture limited the work up of this patient.

In conclusion, this case demonstrates that with the rising prevalence of diabetes in Sub-Saharan Africa, just like in China, cryptococcal meningitis should be considered in the differential diagnosis for diabetic patients presenting with chronic headache accompanied with fever and neurologic deficits [17]. It is important to note that presentations may be dramatic and the outcomes grave due to the paradoxically exaggerated immune response to C. neoformans [18]. The response to fluconazole was satisfactory in this patient. However, effort should be made to avail the more effective combination of amphotericin B and flucytosine in resource poor setting. Modalities like laboratory services to monitor any toxicities should also be availed. Otherwise researchers should endeavor to come up with cheaper, effective but less toxic formulations. A co-positive state with malarial parasites may not preclude the diagnosis, and treatment thereof, of cryptococcal meningitis especially in a malaria-endemic zone. A high index of suspicion may be extremely rewarding in such a presentation.

Notes

Acknowledgements

The authors wish to acknowledge the patient for giving us unhindered opportunity to learn from her medical condition and to write this case report.

Funding

no funding was obtained for this case report.

Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions

OHO took history, examined the patient, analyzed and interpreted the patient information regarding cryptococcal meningitis in diabetes. PC confirmed the physical examination, guided the discussion and was a major contributor in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

not applicable.

Consent for publication

The patient gave her consent for this publication. She signed the BMC consent form.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Kushawaha A, Mobarakai N, Parikh N, Beylinson A. Cryptococcus neoformans meningitis in a diabetic patient - the perils of an overzealous immune response: a case report. Cases Journal. 2009;2:209.  https://doi.org/10.1186/1757-1626-2-209.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Hall V, Thomsen RW, Henriksen O, Lohse N. Diabetes in sub Saharan Africa 1999-2011: epidemiology and public health implications. A systematic review. BMC Public Health. 2011;11:564.  https://doi.org/10.1186/1471-2458-11-564.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Majaliwa ES, et al. Survey on acute and chronic complications in children and adolescents with type 1 diabetes at Muhimbili National Hospital in Dar Es Salaam, Tanzania. Diabetes Care. 2007;30(9):2187–92.  https://doi.org/10.2337/dc07-0594.CrossRefPubMedGoogle Scholar
  4. 4.
    MOH. Cameroon Burden of Diabetes Project (Cambod): Baseline Survey Report. Ministry of Health, Cameroon; 2004.Google Scholar
  5. 5.
    Nakamura K, Yamagishi S, Adachi H. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab Res Rev. 2007;24(2):109–14.  https://doi.org/10.1002/dmrr.766.CrossRefGoogle Scholar
  6. 6.
    Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–21.  https://doi.org/10.1056/NEJMra052723.CrossRefPubMedGoogle Scholar
  7. 7.
    Stehouwer C, Lambert J, Donker A, van Hinsbergh VWM. Endothelial dysfunction an pathogenesis of diabetic angiopathy. Cardiovasc Res. 1997;34:55–68.  https://doi.org/10.1016/S0008-6363(96)00272-6. CrossRefPubMedGoogle Scholar
  8. 8.
    Nandennavar M, Karpurmath S, Santosh KV, Rojaramani P, Ramakrishna NVS. Cryptococcal meningitis in a human immunodeficiency virus negative patient with follicular lymphoma. Indian Journal of Medical and Paediatric Oncology : Official Journal of Indian Society of Medical & Paediatric Oncology. 2014;35(1):118–9.  https://doi.org/10.4103/0971-5851.133739. CrossRefGoogle Scholar
  9. 9.
    Guo L, Liu L, Liu Y, et al. Characteristics and outcomes of cryptococcal meningitis in HIV seronegative children in Beijing, China, 2002–2013. BMC Infect Dis. 2016;16:635.  https://doi.org/10.1186/s12879-016-1964-6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis. 2001;33:690.CrossRefGoogle Scholar
  11. 11.
    MOH. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya, 2016 Edition. Ministry of Health, Kenya; 2016.Google Scholar
  12. 12.
    Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363:1764.CrossRefGoogle Scholar
  13. 13.
    Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368:1291.CrossRefGoogle Scholar
  14. 14.
    Dromer F, Mathoulin-Pélissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21.CrossRefGoogle Scholar
  15. 15.
    Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One. 2008;3:e2870.CrossRefGoogle Scholar
  16. 16.
    Lane M, Mcbride J, Archer J. Steroid responsive late deterioration in Cryptococcus neoformans variety gattii meningitis. Neurology. 2004;63:713–4.CrossRefGoogle Scholar
  17. 17.
    Li Y, Fang W, Jiang W, et al. Cryptococcosis in patients with diabetes mellitus II in mainland China: 1993-2015. Mycoses. 2017 Nov;60(11):706–13.CrossRefGoogle Scholar
  18. 18.
    Lin KH, Chen CM, Chen TL, et al. Diabetes mellitus is associated with acquisition and increased mortality in HIV-uninfected patients with cryptococcosis: a population-based study. J Inf Secur. 2016 May;72(5):608–14.Google Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.School of Medicine, Department of Family MedicineMoi UniversityEldoretKenya

Personalised recommendations